NEWS Release

STOCK OPTIONS GRANTED

Toronto Stock Exchange Trading Symbol: WXI
http://www.wexpharma.com
E-mail: wex@wexpharma.com

.................................................................................................

Vancouver, BC (December 28, 2005) - WEX Pharmaceuticals Inc. (“WEX” or the “Company”) today announced the granting of stock options for 190,000 shares at a price of $1.50 with expiry dates up to December 27, 2010 to certain individuals pursuant to their respective service agreements with the Company.

Dr. Jean Bourgouin, Executive Vice President/CMO, has been granted 100,000 stock options, Dr. Edge Wang, President/CEO, has been granted 50,000 stock options, and an employee and a consultant to the Company has been granted the remaining 40,000 stock options.

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. The Company’s principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market. The Company’s Chinese subsidiary sells generic products manufactured at its facility in China.

Forward Looking Statements

This News Release contains forward-looking statements which may not be based on historical fact, including without limitation statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.

For additional information on our products, visit us at www.wexpharma.com or call Don Evans, V.P. Corporate Communications at 604-683-8880 or 1-800-722-7549.

.................................................................................................